

Amendments to the claims:

**CLAIMS**

1. (original) A process for purification of optically impure Ramipril to obtain Ramipril(I) having optical purity of at least 99.9 %, which comprises crystallizing optically impure Ramipril from an organic solvent selected from nitromethane, dimethoxymethane, diethoxymethane, and 2,2, -dimethoxy propane and mixtures thereof.
2. (original) The process as claimed in claim 1 wherein the organic solvent is diethoxymethane.
3. (original) A monohydrate of Ramipril(I), characterized by the following X-ray powder diffraction pattern

Diffraction angle 2 $\theta$	Relative Intensity (%)
8.7	16
9.2	3
9.4	3
9.7	3
11.2	81
11.6	33
12.2	66
14.54	96
15.7	70
18.0	51
19.7	81
24.5	49
24.8	30

4. (original) The Ramipril(I) monohydrate as claimed in claim 3 having an X-ray diffractogram, or substantially the same X-ray diffractogram, as set out in Figure 1a.
5. (original) The Ramipril(I) monohydrate as claimed in claim 3 having DSC thermogram as described in Fig. 1c.
6. (original) The Ramipril(I) monohydrate as claimed in claim 3 having TGA thermogram as described in Fig. 1d.

7. (original) A process for preparation of Ramipril(l) monohydrate comprising of crystallizing optically impure Ramipril from a mixture of water and water-immiscible solvents.
8. (original) The process claimed in claim 7 wherein the ratio of water-immiscible solvent to water is in the range from 2 to 98% w/w.
9. (original) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from an aliphatic ester, an acetal, a hydrocarbon or a mixture thereof.
10. (original) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from diisopropyl ether, diethoxymethane, 2,2-dimethoxy propane, cyclohexane, methyl isobutyl ketone and ethyl acetate or a mixture thereof.
11. (original) A process for preparation of Ramipril(l) monohydrate comprising of crystallizing optically pure Ramipril(l) from water.
12. (currently amended) A pharmaceutical composition comprising an effective ACE inhibitory amount of Ramipril(l) monohydrate as claimed in ~~any preceding claims~~ claim 3, together with one or more pharmaceutically acceptable carriers, diluents or excipients thereof.